Chinese American Cancer Survivors Writing Study

NCT ID: NCT05456100

Last Updated: 2025-12-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

108 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-07-14

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Chinese American Cancer Survivors Writing Study is a Randomized Controlled Trial (RCT) testing the feasibility and efficacy of the Expressive Helping (EH) intervention among Chinese American cancer survivors.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Chinese Americans are one of the fastest growing immigrant groups in the United States, but there is still a lack of culturally-sensitive and linguistically-appropriate resources and interventions for this group. To address this gap, the investigators will examine the efficacy and feasibility of Expressive Helping, a writing intervention designed to lead participants to write about their cancer experiences. Participants will be adult cancer survivors of Chinese descent. After screening and consent, eligible participants will be enrolled in a 1:1:1 randomized controlled trial. Assessments of psychological symptoms will occur at baseline (prior to randomization), 1-month post-intervention, 3-months post-intervention, and 6-months post-intervention.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Expressive Helping

Participants complete a 20-minute expressive writing session once per week for the first three weeks. During Week 4, participants complete a 20-minute peer support writing session.

Group Type EXPERIMENTAL

Expressive Helping

Intervention Type BEHAVIORAL

Expressive helping involves a combination of emotional disclosure and peer support writing completed over four weeks.

Expressive Writing

Participants complete a 20-minute expressive writing session once per week for four weeks.

Group Type ACTIVE_COMPARATOR

Expressive Writing

Intervention Type BEHAVIORAL

Expressive writing involves emotional disclosure writing over four weeks.

Factual Writing

Participants complete a 20-minute factual writing about their cancer diagnosis and treatment every week for four weeks.

Group Type ACTIVE_COMPARATOR

Factual Writing

Intervention Type BEHAVIORAL

Factual writing involves writing facts about cancer treatment and experiences over four weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Expressive Helping

Expressive helping involves a combination of emotional disclosure and peer support writing completed over four weeks.

Intervention Type BEHAVIORAL

Expressive Writing

Expressive writing involves emotional disclosure writing over four weeks.

Intervention Type BEHAVIORAL

Factual Writing

Factual writing involves writing facts about cancer treatment and experiences over four weeks.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Over 18 years old.
* Prefer speaking in Mandarin Chinese or Cantonese, and able to read and write Simplified or Traditional Chinese.
* Within 5 years after completing primary treatment or have completed primary treatment but still on medication for managing cancer-related symptoms.

Exclusion Criteria

* Difficulties with writing
* Current active participation in support groups (i.e., attending more than once per week)
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

New York University

OTHER

Sponsor Role lead

National Institute on Minority Health and Health Disparities (NIMHD)

NIH

Sponsor Role collaborator

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

New York University

New York, New York, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

William Tsai, PhD

Role: CONTACT

(212)998-5552

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

William Tsai

Role: primary

212-998-5552

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Informed Consent Form

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1K01MD014750

Identifier Type: NIH

Identifier Source: secondary_id

View Link

20-0603

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.